Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program. As of April 23, 2025, the company has repurchased a total of 2,686,825 ordinary fully paid securities, with 62,363 bought back on the previous day. This strategic move is part of the company’s efforts to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is listed on the Australian Securities Exchange under the code NEU and is involved in creating innovative treatments to address unmet medical needs.
YTD Price Performance: -9.02%
Average Trading Volume: 1,133
Technical Sentiment Signal: Hold
Current Market Cap: $864.6M
See more data about NEU stock on TipRanks’ Stock Analysis page.